Advertisement
Clinical Therapeutics
Advanced searchSave search
Research Article| Volume 18, ISSUE 1, P2-34, January 1996

Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents

DOI:https://doi.org/10.1016/S0149-2918(96)80175-5
Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents
Previous ArticleEditorial comment
Next ArticleEditorial comment
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Acid peptic disorders, including gastric ulcers, duodenal ulcers, and gastro-esophageal reflux disease, are commonly occurring conditions with high direct and indirect costs. The pathogenesis of these disorders involves an imbalance between acid secretion and gastric mucosal defenses. Pharmacologic treatment of acid peptic disorders has focused on correcting this imbalance by either improving mucosal defenses with drugs such as sucralfate, bismuth, and prostaglandin analogs, neutralizing acid with antacids, or decreasing acid secretion with histamine2 (H2)-receptor antagonists, or, more recently, proton pump inhibitors. Proton pump inhibitors are more potent inhibitors of acid secretion than H2-receptor antagonis ts. In clinical comparisons, proton pump inhibitors were shown to be more effective in the treatment of acid peptic disorders than H2-receptor antagonists. Helicobacter pylori infection is a factor in 85% to 100% of duodenal ulcers and 70% to 90% of gastric ulcers; eradicating this organism results in a considerable decrease in the recurrence of ulcers. Current management of peptic ulcer disease includes the use of combination antisecretory and antibiotic therapy for acute treatment of H pylori-associated disease. Patient self-medication with over-the-counter products, including H2-receptor antagonists, may have an impact on the potential for reducing the recurrence of peptic ulcer disease in patients with H pylori infection. Patients with recurrent disease should be informed of the need to seek medical treatment through aggressive education at the point of sale for over-the-counter drugs.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Soll AH
        Gastric, duodenal, and stress ulcer.
        in: Sleisenger MH Fordtran JS 5th ed. Gastrointestinal Disease: Pathophysiology/Diagnosis/Management. WB Saunders, Philadelphia1989: 814-879
        • Ihamaki T
        • Varis K
        • Siurala A
        Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Comparison with a computer-matched family sample.
        Scand J Gastroenterol. 1979; 14: 801-812
        • Walsh JH
        Acid peptic disorders of the gastrointestinal tract.
        in: Kelly WN DeVita VTJ 2nd ed. Textbook of Internal Medicine. JB Lippincott, Philadelphia1992: 500-513
        • Kurata J
        • Nogawa A
        • Watanabe Y
        • Kawai K
        Peptic ulcer disease mortality. Comparison of native Japanese, Japanese Americans, and Caucasian Americans.
        J Clin Gastroenterol. 1994; 18: 145-154
        • Jensen DM
        Economic and health aspects of peptic ulcer disease and H2-receptor antagonists.
        Am J Med. 1986; 81 (Suppl 4B): 42-48
        • Von Haunalter G
        • Chandler VV
        Cost of Ulcer Disease in the United States. Stanford Research Institute, Palo Alto, Calif1977 (Project 5894)
        • Orlando RC
        Reflux esophagitis.
        in: Yamada T Alpers DH Textbook of Gastroenterology. JB Lippincott, Philadelphia1991: 1123-1147
        • Tytgat GNJ
        • Rauws EAJ
        Campylobacter pylori and its role in peptic ulcer disease.
        Gastroenterol Clin North Am. 1990; 19: 183-196
        • Dooley CP
        • McKenna D
        • Humphreys H
        • et al.
        Histological gastritis in duodenal ulcer: Relationship to Campylobacter pylori and effect of ulcer therapy.
        Am J Gastroenterol. 1988; 83: 278-282
        • Silvoso GR
        • Ivey KJ
        • Butt JH
        • et al.
        Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy.
        Ann Intern Med. 1979; 91: 517-520
        • Price WE
        • Grizzle JE
        • Postlethwait RW
        • et al.
        Results of operation for duodenal ulcer.
        Surg Gynecol Obstet. 1970; 131: 233-244
        • Richardson CT
        Gastric ulcer.
        in: Sleisenger MH Fordtran JS 4th ed. Gastrointestinal Disease: Pathophysiology, Diagnosis, Management. WB Saunders, Philadelphia1989: 879
        • Savarino V
        • Mela GS
        • Scalabrini P
        • et al.
        24-Hour study of intragastric acidity in duodenal ulcer patients and normal subjects using continuous intraluminal pH-metry.
        Dig Dis Sci. 1988; 33: 1077-1080
        • Merki HS
        • Fimmel CJ
        • Walt RP
        • et al.
        Pattern of 24-hour intragastric acidity in active duodenal ulcer disease and in healthy controls.
        Gut. 1988; 29: 1583-1587
        • Lichtenberger LM
        • Graziani LA
        • Diaql EJ
        • et al.
        Role of surface-active phospholipids in gastric cytoprotection.
        Science. 1983; 219: 1327-1329
        • Macherey HJ
        • Petersen KU
        Rapid decrease in electrical conductance of mammalian duodenal mucosa in vitro.
        Gastroenterology. 1989; 97: 1448-1460
        • Cherry RD
        • Jabbari M
        • Goresky CA
        • et al.
        Chronic mesenteric vascular insufficiency with gastric ulceration.
        Gastroenterology. 1986; 91: 1548-1552
        • Cronstedt J
        • Willen R
        • Balldin G
        • et al.
        Gastroduodenal ulceration in abdominal angina.
        Acta Chir Scand. 1982; 148: 687-692
        • Critchlow J
        • Magee D
        • Ito K
        • et al.
        Requirements for restitution of the surface epithelium of frog stomach after mucosal injury.
        Gastroenterology. 1985; 88: 237-249
        • Silen W
        • Ito S
        Mechanisms for rapid re-epithelialization of the grastric mucosal surface.
        Ann Rev Physiol. 1985; 47: 217-229
        • Chen MC
        • Olson C
        • Tanner M
        • Soll A
        Apical EGF/TGFα receptors mediate enhanced resistance of gastric mucosal cell monolayers to apical acidification.
        Gastroenterology. 1991; 100 (Abstract): 42A
        • Chen MC
        • Lee AT
        • Soll AH
        Mitogenic response of canine fundic epithelial cells in short-term culture to transforming growth factor A and insulin-like growth factor 1.
        J Clin Invest. 1991; 87: 1716-1723
        • Lee AT
        • Chen MC
        • Avedian D
        • Soll AH
        Neurocrine and endocrine regulation of canine fundic mucosal epithelial cell growth.
        Gastroenterology. 1991; 100 (Abstract): A108
        • Bransom CJ
        • Boxer ME
        • Palmer KR
        • et al.
        Mucosal cell proliferation in duodenal ulcer and duodenitis.
        Gut. 1981; 22: 277-282
        • Levi S
        • Goolad RA
        • Lee CY
        • et al.
        Inhibitory effect of nonsteroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing.
        Lancet. 1990; 336: 840-843
        • Isenberg JI
        • Hogan DL
        • Koss MA
        • Selling JA
        Human duodenal mucosal bicarbonate secretion. Evidence for basal secretion and stimulation by hydrochloric acid and a synthetic prostaglandin E1 analogue.
        Gastroenterology. 1986; 91: 370-378
        • Flemstrom G
        • Turnberg LA
        Gastroduodenal defence mechanisms.
        Clin Gastroenterol. 1984; 13: 327-354
        • Kahrilas PJ
        • Gupta RR
        The effect of cigarette smoking on salivation and esophageal acid clearance.
        J Lab Clin Med. 1989; 114: 431-438
        • Jaszewski R
        • Calzada R
        • Dhar R
        Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and entericcoated aspirin.
        Dig Dis Sci. 1989; 34: 1361-1364
        • Selling JA
        • Hogan DL
        • Aly A
        • et al.
        Indomethacin inhibits duodenal mucosal bicarbonate secretion and endogenous prostaglandin E2 output in human subjects.
        Ann Intern Med. 1987; 106: 368-371
        • Kauffman GLJ
        • Aures D
        • Grossman MI
        Intravenous indomethacin and aspirin reduce basal gastric mucosal blood flow in dogs.
        Am J Physiol. 1980; 238: G131-G134
        • Redfern JS
        • Feldman M
        Role of endogenous prostaglandins in preventing gastrointestinal ulceration: Induction of ulcers by antibodies to prostaglandin.
        Gastroenterology. 1989; 96 (Suppl): 596-605
        • Lanza FL
        • Aspinall RL
        • Swabb EA
        • et al.
        Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum.
        Gastroenterology. 1988; 95: 282-294
        • Collins AJ
        • Davies J
        • Dixon AS
        A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis.
        Br J Rheumatol. 1988; 27: 106-109
        • Silverstein FE
        • Graham DY
        • Senior JR
        • et al.
        Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs.
        Ann Intern Med. 1995; 123: 241-249
        • Graham DY
        • Malaty HM
        • Evans DG
        • et al.
        Epidemiology of Helicobacter pylori in an asymptomatic population in the United States: Effect of age, race, and socioeconomic status.
        Gastroenterology. 1991; 100: 1495-1501
        • Jones DM
        • Eldridge J
        • Fox AJ
        • et al.
        Antibody to the gastric campylobacter-like organism—clinical correlations and distribution in the normal population.
        J Med Microbiol. 1986; 22: 57-62
        • Dooley CP
        • Cohen H
        • Fitzgibbons PL
        • et al.
        Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons.
        NEJM. 1989; 321: 1562-1566
        • Marshall BJ
        • Armstrong JA
        • McGechie DB
        • Glancy RJ
        Attempt to fulfill Koch's postulates for pyloric.
        Campylobacter. Med J Aust. 1985; 142: 436-439
        • Koop H
        • Stumpf M
        • Bissele R
        • et al.
        Antral Campylobacter pylori in different states of gastric acid secretion.
        Gastroenterology. 1989; 96 (Abstract): A267
        • Smoot DT
        • Mobley HLT
        • Resau JH
        Inhibition of Campylobacter pylori urease activity prevents gastric epithelial cell injury in vitro.
        Gastroenterology. 1989; 96 (Abstract): A480
        • Slomiany BL
        • Bilski J
        • Sarosiek J
        • et al.
        Campylobacter pylori degrades mucin and undermines gastric mucosal integrity.
        Biochem Biophys Res Commun. 1987; 144: 307-314
        • Sarosiek J
        • Slomiany A
        • VanHorn K
        • et al.
        Lipolytic activity of Campylobacter pylori: Effect of sofalcone.
        Gastroenterology. 1988; 96 (Abstract): A399
        • Leunk RD
        • Johnson PT
        • David BC
        • et al.
        Cytotoxic activity in broth-culture filtrates of Campylobacter pylori.
        J Med Microbiol. 1988; 26: 93-99
        • Marshall BJ
        • Warren JR
        • Blincow ED
        • et al.
        Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.
        Lancet. 1988; 2: 1437-1442
        • Rauws EAJ
        • Tytgat GNJ
        Cure of duodenal ulcer associated with eradication of Helicobacter pylori.
        Lancet. 1990; 335: 1233-1235
        • George LL
        • Barody TJ
        • Andrews P
        • et al.
        Cure of duodenal ulcer after eradication of Helicobacter pylori.
        Med J Aust. 1990; 153: 145-149
        • Coghlan JG
        • Humphries H
        • Dooley C
        • et al.
        Campylobacter pylori and recurrence of duodenal ulcers—a 12-month followup study.
        Lancet. 1987; 2: 1109-1111
        • Graham DY
        • Lew GM
        • Klein PD
        • et al.
        Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer.
        Ann Intern Med. 1992; 116: 705-708
        • The Eurogast Study Group
        An international association between Helicobacter pylori infection and gastric cancer.
        Lancet. 1993; 341: 1359-1362
        • Parsonnet J
        • Friedman GD
        • Vandersteen DP
        • et al.
        Helicobaeter pylori infection and the risk of gastric carcinoma.
        NEJM. 1991; 325: 1127-1131
        • Forman D
        • Newell DG
        • Fullerton F
        • et al.
        Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation.
        BMJ. 1991; 302: 1302-1305
        • Parsonnet J
        • Hansen S
        • Rodriguez L
        • et al.
        Helicobacter pylori infection and gastric lymphoma.
        NEJM. 1994; 330: 1267-1271
        • Aird I
        • Bewtall HH
        • Mehigan JA
        • Roberts JAP
        The blood groups in relation to peptic ulceration and carcinoma of colon, rectum, breast, and bronchus.
        BMJ. 1954; 2: 315-316
        • Ammann RW
        • Vetter D
        • Deyhle P
        • et al.
        Gastrointestinal involvement in systemic mastocytosis.
        Gut. 1976; 17: 107-112
        • Kumar N
        • Kumar A
        • Broor SL
        • et al.
        Effect of milk on patients with duodenal ulcers.
        BMJ. 1986; 293: 666-667
        • Kumar N
        • Vij JC
        • Sarin SK
        • Anand BS
        Do chilies influence healing of duodenal ulcer?.
        BMJ. 1984; 288: 1803-1804
        • Sonnenberg A
        Factors which influence the incidence and course of peptic ulcer.
        Scand J Gastroenterol. 1988; 155 (Suppl): 119-140
        • Kahrilas PJ
        • Hogan WJ
        Gastroesophageal reflux disease.
        in: Sleisenger M Fordtran J 5th ed. Gastrointestinal Disease: Pathophysiology/Diagnosis/Management. WB Saunders, Philadelphia1993: 378-401
        • Chiverton SG
        • Hunt RH
        Smoking and duodenal ulcer disease.
        J Clin Gastroenterol. 1989; 11 (Suppl): S29-S33
        • Sontag S
        • Graham DY
        • Bessito A
        • et al.
        Cimetidine, cigarette smoking, and recurrence of duodenal ulcer.
        NEJM. 1984; 311: 689-693
        • Soll AH
        Pathogenesis of peptic ulcer and implications for therapy.
        NEJM. 1990; 322: 909-916
        • Muller-Lissner SA
        Bile reflux is increased in cigarette smokers.
        Gastroenterology. 1986; 90: 1205-1209
        • Weiner H
        • Thaler M
        • Reiser MF
        • Mirsky IA
        Etiology of duodenal ulcer. I. Relation of specific psychological characteristics to rate of gastric secretion (serum pepsinogen).
        Psychosom Med. 1957; 19: 1-11
        • Holtmann G
        • Armstrong D
        • Poppel E
        • et al.
        Influence of stress on the healing and relapse of duodenal ulcers: A prospective, multicenter trial of 2109 patients with recurrent duodenal ulceration treated with ranitidine.
        Scand J Gastroenterol. 1992; 27: 917-923
        • Bresnick WH
        • Rask-Madsen C
        • Hogan DL
        • et al.
        The effect of acute emotional stress on gastric acid secretion in normal subjects and duodenal ulcer patients.
        J Clin Gastroenterol. 1993; 17: 117-122
        • Weiner H
        From simplicity to complexity (1950–1990): The case of peptic ulceration—II. Animal studies.
        Psychosom Med. 1991; 53: 491-516
        • Piper DW
        • McIntosh JH
        • Ariotti DE
        • et al.
        Life events and chronic duodenal ulcer: A case control study.
        Gut. 1981; 22: 1101-1107
        • Gudjonsson B
        • Spiro HM
        Response to placebos in ulcer disease.
        Am J Med. 1978; 65: 399-402
        • Walan A
        • Bader JP
        • Classen M
        • et al.
        Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer.
        NEJM. 1989; 320: 69-75
        • Domschke W
        • Hagel J
        • Ruppin H
        • et al.
        Antacids and gastric mucosal protection.
        Scand J Gastroenterol. 1986; 21 (Suppl 125): 144-150
        • Preclik G
        • Stange EF
        • Gerber K
        • et al.
        Stimulation of mucosal prostaglandin synthesis in human stomach and duodenum by antacid treatment.
        Gut. 1989; 30: 148-151
        • Hollander D
        • Tarnawski A
        Are antacids cytoprotective?.
        Gut. 1989; 30: 145-147
        • Berstad A
        • Alexander B
        • Weberg R
        • et al.
        Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes.
        Gastroenterology. 1988; 95: 619-624
        • Marshall BJ
        • Armstrong JA
        • Francis GJ
        • et al.
        Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis.
        Digestion. 1983; 37 (Suppl 2): 16-30
        • Texter EC
        A critical look at the clinical use of antacids in acid-peptic disease and gastric acid rebound.
        Am J Gastroenterol. 1989; 84: 97-108
        • Steinberg WM
        • Lewis JH
        • Katz DM
        Antacids inhibit absorption of cimetidine.
        NEJM. 1980; 307: 400-404
        • Nagashima R
        Development and characteristics of sucralfate.
        J Clin Gastroenterol. 1981; 3 (Suppl 2): 103-110
        • Konturek SJ
        • Brzozowski T
        • Bielanski W
        • et al.
        Epidermal growth factor in the gastroprotective and ulcer-healing actions of sucralfate in rats.
        Am J Med. 1989; 86: 32-37
        • Szabo S
        • Hollander D
        Pathways of gastrointestinal protection and repair: Mechanisms of action of sucralfate.
        Am J Med. 1989; 86: 23-31
        • Shorrock C
        • Rees W
        Effect of sucralfate on human gastric bicarbonate secretion and local prostaglandin E2 metabolism.
        Am J Med. 1989; 86: 2-4
        • Takemoto T
        • Kimura K
        • Okita K
        • et al.
        Efficacy of sucralfate in the prevention of recurrence of peptic ulcer: Double blind multicenter study with cimetidine.
        Scand J Gastroenterol. 1987; 22 (Suppl 140): 49-60
        • Brandstaetter G
        • Kratochirl P
        Comparison of two sucralfate dosages (2 gms twice a day versus four times a day) in duodenal ulcer healing.
        Am J Med. 1985; 79 (Suppl 2C): 36-38
        • Marks IN
        • Wright JD
        • Gilinsky NH
        • et al.
        A comparison of sucralfate dosage schedules in duodenal ulcer healing.
        J Clin Gastroenterol. 1986; 8: 419-423
        • Schubert T
        Twice daily sucralfate dosing to heal acute duodenal ulcer.
        Am J Med. 1989; 86 (Suppl 6A): 108-112
        • Walker JA
        • Sherman RA
        • Cody RP
        The effect of oral bases on central aluminum absorption.
        Arch Intern Med. 1990; 50: 2037-2039
        • Garretts JC
        • Godley PJ
        • Peterie JD
        • et al.
        Sucralfate significantly reduces ciprofloxacin concentrations in serum.
        Antimicrob Agents Chemother. 1990; 34: 931-933
        • Shields HM
        Rapid fall of serum phosphorus secondary to antacid therapy.
        Gastroenterology. 1978; 75: 1137-1141
        • Smith AC
        • Price AB
        • Borriello P
        • Levi AJ
        A comparison of ranitidine and tripotassium dicitrate-bismuth in relapse rates of duodenal ulcer. The role of Campylobacter pylori.
        Gastroenterology. 1988; 94 (Abstract): A431
        • Szabo S
        • Vattay P
        • Scarbrough E
        • Folkman J
        Role of vascular factors, including angiogenesis, in the mechanisms of action of sucralfate.
        Am J Med. 1991; 91: 158S-160S
        • Nwokolo CU
        • Mistry P
        • Pounder RE
        The absorption of bismuth and salicylate from oral doses of Pepto-Bismol (bismuth salicylate).
        Aliment Pharmacol Ther. 1990; 4: 163-169
        • Wagstaff AJ
        • Benfield P
        • Monk JP
        Colloidal bismuth subcitrate: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in peptic ulcer disease.
        Drugs. 1988; 36: 132-157
        • Weller MP
        Neuropsychiatric symptoms following bismuth intoxication.
        Postgrad Med J. 1988; 64: 308-310
        • Ebell MH
        Peptic ulcer disease.
        Am Fam Physician. 1992; 46: 217-227
        • Monk JP
        • Clissold SP
        Misoprostol: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of peptic ulcer disease.
        Drugs. 1987; 33: 1-30
        • Roth S
        • Agrawal N
        • Mahowald M
        • et al.
        Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin.
        Arch Intern Med. 1989; 149: 775-779
        • Graham DY
        • Agrawal NM
        • Roth SH
        Prevention of NSAID induced gastric ulcer with misoprostol: Multicenter, double-blind, placebo controlled trial.
        Lancet. 1988; 2: 1277-1280
        • Thomas JM
        • Misiewicz G
        Histamine H2-receptor antagonists in the short- and long-term treatment of duodenal ulcer.
        Clin Gastroenterol. 1984; 13: 501-541
        • Feldman M
        • Burton ME
        Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. Part II.
        NEJM. 1990; 323: 1749-1755
        • Hunt RH
        • Howden CW
        • Jones DB
        • et al.
        The correlation between acid suppression and peptic ulcer healing.
        Scand J Gastroenterol. 1986; 125 (Suppl): 22-31
        • McArthur KE
        • Raufman J-P
        • Seaman JJ
        • et al.
        Cimetidine pharmacokinetics in patients with Zollinger-Ellison syndrome.
        Gastroenterology. 1987; 93: 69-76
        • Wilder-Smith CH
        • Ernst T
        • Gennoni M
        • et al.
        Tolerance to H2-receptor antagonists.
        Dig Dis Sci. 1990; 35: 976-983
        • Salnikowicz-Darvasi R
        H2-antagonists in the treatment of reflux esophagitis: A critical analysis.
        Am J Gastroenterol. 1989; 98 (Abstract): A130
        • Koelz HR
        • Birchler A
        • Bretholz B
        • et al.
        Healing and relapse of reflux esophagitis during treatment with ranitidine.
        Gastroenterology. 1986; 91: 1198-1205
        • Johnson NJ
        • Boyd EJ
        • Mills JG
        • Wood JR
        Acute treatment of reflux oesophagitis: A multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s..
        Aliment Pharmacol Ther. 1989; 3: 259-266
        • Lipsy RJ
        • Fennerty B
        • Fagan TC
        Clinical review of the histamine-2 receptor antagonists.
        Arch Intern Med. 1990; 150: 745-751
        • Feldman M
        • Burton ME
        Histamine2-receptor antagonists: Standard therapy for acid-peptie disease. Part I.
        NEJM. 1990; 323: 1672-1680
        • McCarthy DM
        Ranitidine or cimetidine?.
        Ann Intern Med. 1983; 99 (Editorial): 551-553
        • Cantu TG
        • Korek JS
        Central nervous system reactions to histamine2-receptor blockers.
        Ann Intern Med. 1991; 114: 1027-1034
        • Maton PN
        Omeprazole.
        NEJM. 1991; 324: 965-975
        • Sharma B
        • Walt RP
        • Pounder RE
        • et al.
        Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.
        Gut. 1984; 25: 957-964
        • Bardhan KD
        • Bianchi PG
        • Bose K
        • et al.
        A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers.
        J Clin Gastroenterol. 1986; 8: 408-413
        • Classen M
        • Dammann H-G
        • Domschke W
        • et al.
        Omeprazole heals duodenal but not gastric ulcers more rapidly than ranitidine.
        Hepatogastroenterology. 1985; 32: 243-245
        • Archambault A
        • Pare P
        • Bailey R
        • et al.
        Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief.
        Gastroenterology. 1988; 94: 1130-1134
        • Lauritsen K
        • Rune SJ
        • Bytzer P
        • et al.
        Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial.
        NEJM. 1985; 312: 958-961
        • McFarland RJ
        • Bateson MC
        • Green JRB
        • et al.
        Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine.
        Gastroenterology. 1990; 98: 278-283
        • Valenzuela JE
        • Berlin RG
        • Snape WJ
        • et al.
        U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.
        Dig Dis Sci. 1991; 36: 761-768
        • Kager L
        • Lindberg G
        • Nilsson LH
        • et al.
        The effect of omeprazole and ranitidine on ulcer healing, relief of symptoms, and incidence of adverse events in the treatment of duodenal ulcer patients.
        Hepatogastroenterology. 1991; 38: 287-290
        • Licht H
        • Andrieu J
        • Bognel JC
        • et al.
        Lansoprazole versus ranitidine dans le traitement des ulceres duodenaux: Resultats d'un essai multicentrique controle, randomise, en double insu sur groupes paralleles.
        Actual Ther. 1990; 19: 251-255
        • Hawkey CJ
        • Long RG
        • Bardhan KD
        • et al.
        Improved symptom relief and duodenal culer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.
        Gut. 1993; 34: 1458-1462
        • Lanza F
        • Goff J
        • Snowcroft C
        • et al.
        Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer.
        Am J Gastroenterol. 1994; 89: 1191-1200
        • Bate CM
        • Wilkinson SP
        • Bradby GVH
        • et al.
        Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer.
        Gut. 1989; 30: 1323-1328
      123. a
        • Michel P
        • Lemaire M
        • Colin R
        • et al.
        Short report: Treatment of gastric ulcer with lansoprazole or ranitidine: A multicentre clinical trial.
        Aliment Pharmacol Ther. 1994; 8: 119-122
      124. bAliment Pharmacol Ther. 1994; 8 (Erratum appears in): 357
        • Bardhan KD
        • Ahlberg J
        • Hislop WS
        • et al.
        Rapid healing of gastric ulcers with lansoprazole.
        Aliment Pharmacol Ther. 1994; 8: 215-220
        • Van Deventer G
        • Cagiola A
        • Whipple J
        • et al.
        Duodenal ulcer healing with omeprazole: A multicenter, double-blind, ranitidine controlled study.
        Gastroenterology. 1988; 94 (Abstract): A476
        • Petite JP
        • Slama JL
        • Licht H
        • et al.
        Comparaison du lansoprazole (30 mg) et de l'oméprazole (20 mg) dans le traitement de l'ulcèr duodénal. Esais theérapeutiques multicentriques comparatif en double aveugle.
        Gastroenterol Clin Biol. 1993; 17: 334-340
        • Ekström P
        • Unge P
        • Carling L
        • et al.
        Lansoprazole vs omeprazole in active ulcer: A healing study.
        Gastroenterology. 1993; 104 (Abstract): 74
        • Tolman KG
        • Sanders SW
        • Buchi KN
        Gastric pH levels after 15 mg and 30 mg of lansoprazole and 20 mg omeprazole.
        Gastroenterology. 1994; 106 (Abstract): A197
        • Hussein Z
        • Granneman R
        • Mukherjee D
        • et al.
        Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.
        Br J Clin Pharmacol. 1993; 36: 391-398
        • Delchier J-C
        • Isal J-P
        • Eriksson S
        • Soule J-C
        Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers.
        Gut. 1989; 30: 1173-1178
        • Bardhan KD
        • Naesdal J
        • Bianchi PG
        • et al.
        Treatment of refractory peptic ulcer with omeprazole or continued H2-receptor antagonists: A controlled clinical trial.
        Gut. 1991; 32: 435-438
        • Brunner G
        • Arnold R
        • Hennig U
        • Fuchs W
        An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
        Aliment Pharmacol Ther. 1993; 7 (Suppl 1): 51-55
        • Bate CM
        • Keeling PWN
        • O'Morain CA
        • et al.
        Omeprazole provides faster healing and symptom relief of reflux oesophagitis than cimetidine.
        Gut. 1989; 30 (Abstract): A1493
        • Sandmark S
        • Carlsson R
        • Fausa O
        • L Lundell
        Omeprazole or ranitidine in the treatment of reflux esophagitis: Results of a double-blind, randomized, Scandinavian multicenter study.
        Scand J Gastroenterol. 1988; 23: 625-632
        • Havelund T
        • Laursen LS
        • Skoubu-Kristensen E
        • Andersen BN
        Omeprazole and ranitidine in treatment of reflux oesophagitis: Double blind comparative trial.
        BMJ. 1988; 296: 89-92
        • Bardhan KD
        • Hawkey CJ
        • Long R
        • et al.
        Lansoprazole versus ranitidine for the treatment of reflux esophagitis.
        Aliment Pharmacol Ther. 1995; 9: 145-151
        • Robinson M
        • Sahba B
        • Avner D
        • et al.
        A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis.
        Aliment Pharmacol Ther. 1995; 9: 25-31
        • Hallerbäck B
        • Unge P
        • Carling L
        • et al.
        Omeprazole or ranitidine in long-term treatment of reflux esophagitis.
        Gastroenterology. 1994; 107: 1305-1311
        • Dent J
        • Yeomans ND
        • Mackinnon M
        • et al.
        Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.
        Gut. 1994; 35: 590-598
        • Lundell L
        • Backman L
        • Ekström P
        • et al.
        Prevention of relapse of reflux esophagitis after endoscopic healing: The efficacy and safety of omeprazole compared with ranitidine.
        Scand J Gastroenterol. 1991; 26: 248-256
        • Feldman M
        • Harford WV
        • Fisher RS
        • et al.
        Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K+-ATPase inhibitor: A controlled, double-blind study.
        Am J Gastroenterol. 1993; 88: 1212-1217
        • Prichard PJ
        • Yeoman NK
        • Mihaly GU
        • et al.
        Omeprazole: A study of its inhibition of gastric pH and oral pharmacokinetics after morning and evening dosage.
        Gastroenterology. 1985; 88: 64-69
        • Sanders SW
        • Tolman KG
        • Greski PA
        • et al.
        The effects of lansoprazole, a new H+,K+-ATPase inhibitor on gastric pH and serum gastrin.
        Aliment Pharmacol Ther. 1992; 6: 359-372
        • Gugler R
        • Jensen JC
        Omeprazole inhibits oxidative drug metabolism: Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.
        Gastroenterology. 1985; 89: 1235-1241
        • Lefebvre RA
        • Flouvat B
        • Kardac-Tamisier S
        • et al.
        Influence of lansoprazole treatment on diazepam plasma concentrations.
        Clin Pharmacol Ther. 1992; 52: 458-463
        • Karol MD
        • Mukhergi D
        • Cavanaugh JH
        Lack of effect of concomitant multi-dose lansoprazole on single-dose phenytoin pharmacokinetics in subjects.
        Gastroenterology. 1994; 106 (Abstract): A103
        • Cavanaugh JH
        • Winters EP
        • Cohen A
        • et al.
        Lack of effect of lansoprazole on steady-state warfarin metabolism.
        Gastroenterology. 1991; 100 (Abstract): A40
        • Gugler R
        • Jensen JC
        Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo.
        Pharmacol Ther. 1987; 31: 133-137
        • Granneman G
        • Winters EP
        • Locke CS
        • et al.
        Lack of effect of concomitant lansoprazole on steady-state theophylline pharmacokinetics.
        Gastroenterology. 1991; 100 (Abstract): A75
        • Cederberg C
        • Anderson T
        • Shankberg I
        Omeprazole: Pharmacokinetics and metabolism in man.
        Scand J Gastroenterol. 1989; 166 (Suppl): 33-40
        • Flouvat B
        • Delhotal-Landes B
        • Cournot A
        • et al.
        Pharmacokinetic study of lansoprazole after oral administration to elderly subjects, comparison to young subjects.
        Eur J Drug Metab Pharmacokinet. 1990; 15 (Abstract): 43
      153. a
        • Solvell L
        The clinical safety of omeprazole.
        Digestion. 1990; 47 (Suppl 1): 59-63
      154. b
        • Solvell L
        The clinical safety of omeprazole.
        Digestion. 1990; 47 (Suppl 1): 76
        • Colin-Jones DG
        Safety of lansoprazole.
        Aliment Pharmacol Ther. 1993; 7 (Suppl 1): 56-66
        • Ekman L
        • Hansson E
        • Havu N
        • et al.
        Toxicologic studies on omeprazole.
        Scand J Gastroenterol. 1985; 20: 53-69
        • Tielemans Y
        • Hakanson R
        • Sundler F
        • Willems G
        Proliferation of enterochromaffin-like cells in omeprazole-treated hypergastrinemic rats.
        Gastroenterology. 1989; 96: 723-729
        • Misawa T
        • Chijiiwa Y
        • Imazono Y
        • et al.
        Effects of lansoprazole, a gastric proton pump inhibitor, on endocrine function and healing in patients with peptic ulcer.
        Ther Res. 1991; 122: 175-189
        • Ogoshi K
        • Kato T
        • Saito S
        • et al.
        Clinical study of AG-1749 (lansoprazole): Effects on serum gastrin levels and gastric mucosal ECL cell density.
        Yakuri Chiryo. 1991; 19: 933-946
        • Larsson H
        • Carlsson E
        • Hakanson R
        • et al.
        Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion.
        Gastroenterology. 1988; 95: 1477-1486
        • Larsson C
        • Skogseid B
        • Oberg K
        • et al.
        Multiple endocrine neoplasia type I gene maps to chromosome 11 and is lost in insulinoma.
        Nature. 1988; 332: 85-87
        • Metz DC
        • Pisegna JR
        • Ringham GL
        • et al.
        Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
        Dig Dis Sci. 1993; 38: 245-256
        • Iwahi T
        • Satoh H
        • Nakao M
        • et al.
        Lansoprazole a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
        Antimicrob Agents Chemother. 1991; 35: 490-496
        • Unge P
        • Gad A
        • Eriksson K
        • et al.
        Amoxicillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients.
        Eur J Gastroenterol Hepatol. 1993; 5: 325-331
        • Bayerdorffer E
        • Miehlke S
        • Mannes GA
        • et al.
        Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers.
        Gastroenterology. 1995; 108: 1412-1417
        • Burette A
        • Glupczynski Y
        • Deprez C
        • Crombez A
        Lansoprazole plus roxithromycin and metronidazole for eradication of Helicobacter pylori: Results of a single blind pilot study.
        Gastroenterology. 1993; 104 (Abstract): 49
        • Logan RP
        • Gummett PA
        • Schaufelberger HD
        • et al.
        Eradication of Helicobacter pylori with clarithromycin and omperazole.
        Gut. 1994; 35: 323-326
        • Harris AW
        • Gummett PA
        • Logan RPH
        • et al.
        Eradication of Helicobacter pylori (Hp) with lansoprazole and clarithromycin.
        Am J Gastroenterol. 1994; 89 (Abstract): 1373
        • Cayla R
        • Zerbib F
        • de Mascarel A
        • et al.
        High dose of lansoprazole in combination with amoxicillin and clarithromycin twice daily for H. pylori eradication: Results of a pilot study.
        Am J Gastroenterol. 1994; 89: 1367
        • de Boer W
        • Driessen W
        • Jansz A
        • Tytgat G
        Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection.
        Lancet. 1995; 345: 817-820
        • Forbes GM
        • Glaser ME
        • Cullen DJ
        • et al.
        Duodenal ulcer treated with Helicobacter pylori eradication: Seven year follow-up.
        Lancet. 1994; 343: 258-260
        • Parente F
        • Lazzaroni M
        • Sangaletti O
        • et al.
        Short- and long-term outcome of HP positive resistant duodenal ulcers treated with colloidal bismuth subcitrate (CBS) plus antibiotics or sucralfate.
        Gastroenterology. 1992; 102 (Abstract): A142
        • Bieberdorf FA
        • Walsh JH
        • Fordtran JS
        Effect of optimum therapeutic dose of poldine on acid secretion, gastric acidity, gastric emptying, and serum concentration after a protein meal.
        Gastroenterology. 1975; 68: 50-57
        • Koelz HR
        Protective drugs in the treatment of gastroduodenal ulcer disease.
        Scand J Gastroenterol. 1986; 21 (Suppl 125): 156-164
        • Van Deventer GM
        • Schneidman D
        • Walsh JH
        Sucralfate and cimetidine as single agents and combination for treatment of active duodenal ulcers. A double-blind placebo-controlled trial.
        Am J Med. 1985; 79: 39-44
        • Arakawa T
        • Higuchi K
        • Fukuda T
        • et al.
        H122-receptor antagonist-refractory ulcer: Its pathophysiology and treatment.
        J Clin Gastroenterol. 1991; 31 (Suppl): 129-133
        • Bianchi PG
        • Parente F
        Long-term treatment of duodenal ulcer. A review of management options.
        Drugs. 1991; 41: 38-51
        • Jensen RT
        • Metz DC
        • Koviack PD
        • Feigenbaum KM
        Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome.
        Aliment Pharmacol Ther. 1993; 7: 41-50
        • Klinkenberg-Knol EC
        • Festen HPM
        • Jansen JBMJ
        • et al.
        Long term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety.
        Ann Intern Med. 1994; 121: 161-167
        • Sampliner R
        Effect of up to 3 years of high dose lansoprazole on Barrett's esophagus.
        Am J Gastroenterol. 1994; 89: 1844-1848

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0149-2918(96)80175-5

      Copyright

      © 1996 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX